fbpx

Scroll down for references for this edition

PASSWORD:  Diabetes Management Journal is a medical journal exclusively for healthcare professionals. Apply for access here:

DMJ Access Application
Image

Diabetes Management Journal
February 2024 References

NEWS & VIEWS REFERENCES  


From the Ed’s desk - Climate change and diabetes

  1. Wong C. Earth just had its hottest year on record — climate change is to blame. Nature [Internet]. 2023 Nov 10; Available from: https://www.nature.com/articles/d41586-023-03523-3

  2. Zilbermint M. Diabetes and climate change. Journal of Community Hospital Internal Medicine Perspectives. 2020 Sep 2;10(5):409–12.

  3. Bowe B, Xie Y, Li T, Yan Y, Xian H, Al-Aly Z. The 2016 global and national burden of diabetes mellitus attributable to PM 2·5 air pollution. The Lancet Planetary Health [Internet]. 2018 Jul;2(7):e301–12. Available from: https://www.sciencedirect.com/science/article/pii/S2542519618301402?via%3Dihub

  4. Gu X, Drouin-Chartier JP, Sacks FM, Hu FB, Rosner B, Willett WC. Red meat intake and risk of type 2 diabetes in a prospective cohort study of United States females and males. The American Journal of Clinical Nutrition [Internet]. 2023 Oct 19; Available from: https://www.sciencedirect.com/science/article/pii/S0002916523661192

  5. Malik A, Lenzen M, McAlister S, McGain F. The carbon footprint of Australian health care. The Lancet Planetary Health [Internet]. 2018 Jan;2(1):e27–35. Available from: https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(17)30180-8/fulltext

  6. Reportback: The innovative EPIC Program to reduce single-use plastic in healthcare [Internet]. Climate and Health Alliance. [cited 2023 Dec 13]. Available from: https://www.caha.org.au/epic_program

  7. Richie C. Environmental sustainability and the carbon emissions of pharmaceuticals. Journal of Medical Ethics. 2021 Apr 14;medethics-2020-106842.

  8. An innovative insulin pen recycling scheme - Plastics le Mag [Internet]. Nom du site. [cited 2023 Dec 13]. Available from: https://plastics-themag.com/An-innovative-insulin-pen-recycling-scheme#:~:text=Recycling%20and%20valorising%20millions%20of%20insulin%20injector%20pens&text=After%20using%20the%20pen%2C%20they

Metformin may reduce the risk of developing long COVID

  1. World Health Organization (2022). Post COVID-19 condition (Long COVID). [online] www.who.int. Available at: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition.

  2. Bramante C, Buse J, Liebovitz D, et al. Outpatient treatment of covid-19 and incidence of post-covid-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis 2023;(June). doi:10.1016/S1473-3099(23)00299-2.

  3. Wise J. Covid-19: Metformin reduces the risk of developing long term symptoms by 40%, study finds. BMJ [Internet]. 2023 Jun 8;381:p1306. Available from: https://www.bmj.com/content/381/bmj.p1306

  4. Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. New England Journal of Medicine. 2022 Aug 18;387(7):599–610.

The latest on statins & diabetes risk

  1. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England journal of medicine [Internet]. 2008;359(21):2195–207. Available from: https://www.ncbi.nlm.nih.gov/pubmed/18997196

  2. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (London, England) [Internet]. 2010;375(9716):735–42. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20167359/

  3. Lee YJ, Hong SJ, Kang WC, Hong BK, Lee JY, Lee JB, et al. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ [Internet]. 2023 Oct 18;383:e075837. Available from: https://www.bmj.com/content/383/bmj-2023-075837

FEATURE REFERENCES

p7-10 Diabetes, CVD & CKD in the era of SGLT-2 inhibitors & GLP-1RAs

  1. Baker Heart and Diabetes Institute [Internet]. Melbourne (AU): 2017. Shaw J, Thomas M, Magliano D. The dark heart of type 2 diabetes 2017 https://baker.edu.au/impact/advocacy/dark-heart-diabetes#:~:text=The%201.5%20million%20Australians%20living,to%20those%20without%20the%20condition.

  2. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339-52.

  3. Management of type 2 diabetes: A handbook for general practice. In: Practitioners. TRACoG, editor. East Melbourne, VIC.2020.

  4. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023. Diabetes Care. 2022;46(Supplement_1):S158-S90.

  5. National Heart Foundation of Australia [Internet]. 2023. 2023 Guideline for assessing and managing CVD risk and Australian CVD risk calculator 2023 [Available from: https://www.heartfoundation.org.au/bundles/for-professionals/guideline-for-managing-cvd.

  6. The FSI. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]. Cardiovascular Diabetology. 2004;3(1):.

  7. Striepe K, Jumar A, Ott C, Karg MV, Schneider MP, Kannenkeril D, et al. Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus. Circulation. 2017;136(12):1167-9.

  8. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28.

  9. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016;134(10):752-72.

  10. Karalliedde J, Winocour P, Chowdhury TA, De P, Frankel AH, Montero RM, et al. Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease. Diabet Med. 2022;39(4):e14769.

  11. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373(22):2117-28.

  12. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine. 2020;383(15):1413-24.

  13. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021;385(16):1451-61.

  14. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2018;380(4):347-57.

  15. van Norman M, Molony DA. KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD. Ann Intern Med. 2023;176(5):Jc50.

  16. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2020;383(15):1436-46.

  17. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2022;388(2):117-27.

  18. Zala A, Maple-Brown LJ, Shaw JE, Hare MJ. Current evidence and practical guidance for the use of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes. Aust J Gen Pract. 2021;50(4):225-30.

  19. Bain SC, Klufas MA, Ho A, Matthews DR. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. Diabetes Obes Metab. 2019;21(3):454-66.

  20. Lim SW, van Wijngaarden P, Harper CA, Al-Qureshi SH. Early worsening of diabetic retinopathy due to intensive glycaemic control. Clin Exp Ophthalmol. 2019;47(2):265-73.

  21. Simó R, Franch-Nadal J, Vlacho B, Real J, Amado E, Flores J, et al. Rapid Reduction of HbA1c and Early Worsening of Diabetic Retinopathy: A Real-world Population-Based Study in Subjects With Type 2 Diabetes. Diabetes Care. 2023;46(9):1633-9.

  22. Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691-704.

  23. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425-35.

  24. Brown JC, Dryburgh JR. A gastric inhibitory polypeptide. II. The complete amino acid sequence. Can J Biochem. 1971;49(8):867-72.

  25. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2(8571):1300-4.

  26. Therapeutic Goods Aministration [Internet]. Woden (AU): TGS; 2023. About the Ozempic (semaglutide) shortage 2022 and 2023 2023 Sep 21 [Available from: https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-ozempic-semaglutide-shortage-2022-and-2023.

  27. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63(2):492-8.

  28. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5):E981-8.

  29. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-39.

  30. Drucker DJ. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metab. 2016;24(1):15-30.

  31. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962-5.

  32. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52.

  33. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375(4):311-22.

  34. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375(19):1834-44.

  35. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394(10193):121-30.

  36. Hughes S, Neumiller JJ. Oral Semaglutide. Clin Diabetes. 2020;38(1):109-11.

  37. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-51.

  38. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503-15.

  39. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-24.

  40. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-26.

  41. Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. Jama. 2018;319(15):1580-91.

  42. Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. Bmj. 2014;348:g2366.

  43. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-15.

  44. Vilsbøll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simó R, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889-97.

  45. Du L, Qin J, Wang D, Zhao Y, Xu N, Wu C, et al. Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients. Front Physiol. 2022;13:1028486.

  46. Castellana M, Cignarelli A, Brescia F, Perrini S, Natalicchio A, Laviola L, et al. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis. Sci Rep. 2019;9(1):19351.

  47. Australian Diabetes Society [Internet]. Sydney (AU): ADS; 2023. Australian Type 2 Diabetes Glycaemic Management Algorithm (May 2023) 2023 May [Available from: https://www.diabetessociety.com.au/guideline/australian-type-2-diabetes-glycaemic-management-algorithm-august-2022/.

  48. NPS MedicineWise [Internet]. Sydney (AU): 2015. SGLT2 inhibitor listings: indications and combinations 2015 Apr 1 [Available from: https://www.nps.org.au/radar/articles/sglt2-inhibitor-listings-indications-and-combinations.

  49. Mark PB, Sarafidis P, Ekart R, Ferro CJ, Balafa O, Fernandez-Fernandez B, et al. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrology Dialysis Transplantation. 2023.

  50. Ng E, Shaw J, Wood A, Maple-Brown L, Hare M. Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes. Australian Journal for General Practitioners. 2022;51:513-8.

  51. Hayashi Y. Glucagon regulates lipolysis and fatty acid oxidation through inositol triphosphate receptor 1 in the liver. Journal of Diabetes Investigation. 2021;12(1):32-4.

  52. Dutta P, Kumar Y, Babu AT, Giri Ravindran S, Salam A, Rai B, et al. Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond. Cureus. 2023;15(5):e38379.

p12-14 Alternative models of care for people with T2D

  1. Diabetes: Australian facts, All diabetes [Internet]. Australian Institute of Health and Welfare. 2023. Available from: https://www.aihw.gov.au/reports/diabetes/diabetes/contents/how-common-is-diabetes/total-diabetes

  2. Parsons M, Luu J, Acharya S, Philcox A. Diabetes Alliance in the Hunter and New England region. International Journal of Integrated Care. 2018 Mar 12;18(s1):43.

  3. Acharya S, Philcox AN, Parsons M, Suthers B, Luu J, Lynch M, et al. Hunter and New England Diabetes Alliance: innovative and integrated diabetes care delivery in general practice. Aust J Prim Health. 2019.

  4. The Royal Australian College of General Practitioners. Management of type 2 diabetes: A handbook for general practice. East Melbourne, Victoria: RACGP; 2020.

  5. Harris ML, Kuzulugil D, Parsons M, Byles J, Acharya S. "They were all together ... discussing the best options for me": Integrating specialist diabetes care with primary care in Australia. Health Soc Care Community. 2021;29(5):e135-e43.

  6. Acharya S, Taylor R, Parsons M et al. An Australian integrated model of care improves health outcomes of patients with type 2 diabetes in primary care practices. Oral presentation Australasian Diabetes Society meeting 13 August 2021

  7. Alexis Hure et al Diabetes Alliance Program: A story of increasing scale and success Implementation science health conference Australia 23-24 March 2023 poster presentation

p16-18 Exercise physiology and its role in the management of T2D

  1. Hemmingsen B, Gimenez-Perez G, Mauricio D, Roqué i Figuls M, Metzendorf MI, Richter B. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database of Systematic Reviews [Internet]. 2017 Dec 4;12(12). Available from: https://www.cochrane.org/CD003054/ENDOC_diet-physical-activity-or-both-prevention-or-delay-type-2-diabetes-mellitus-and-its-associated

  2. Slentz CA, Bateman LA, Willis LH, Granville EO, Piner LW, Samsa GP, et al. Effects of exercise training alone vs a combined exercise and nutritional lifestyle intervention on glucose homeostasis in prediabetic individuals: a randomised controlled trial. Diabetologia [Internet]. 2016 Jul 15;59(10):2088–98. Available from: https://link.springer.com/article/10.1007%2Fs00125-016-4051-z

  3. Umpierre D. Physical Activity Advice Only or Structured Exercise Training and Association With HbA1cLevels in Type 2 Diabetes. JAMA. 2011 May 4;305(17):1790-9.

  4. Phung OJ. Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes. JAMA [Internet]. 2010 Apr 14;303(14):1410. Available from: https://jamanetwork.com/journals/jama/fullarticle/185654

  5. Wrench E, Rattley K, Lambert JE, Killick R, Hayes LD, Lauder RM, et al. There is no dose–response relationship between the amount of exercise and improvement in HbA1c in interventions over 12 weeks in patients with type 2 diabetes: a meta-analysis and meta-regression. Acta Diabetologica. 2022 Aug 5;59(11):1399–415

  6. Motiani KK, Collado MC, Eskelinen JJ, Virtanen KA, Loyttyniemi E, Salminen S et al. Exercise Training Modulates Gut Microbiota Profile and Improves Endotoxemia. Medicine & Science in Sports & Exercise. 2020;52(1):94-104.

  7. Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes: One-year results of the Look AHEAD trial. Diabetes Care. 2007 Mar 15;30(6):1374–83.

  8. Way KL, Keating SE, Baker MK, Chuter VH, Johnson NA. The Effect of Exercise on Vascular Function and Stiffness in Type 2 Diabetes: A Systematic Review and Meta-analysis. Curr Diabetes Rev. 2016;12(4):369-83.

  9. Hordern MD, Coombes JS, Cooney LM, Jeffriess L, Prins JB, Marwick TH. Effects of exercise intervention on myocardial function in type 2 diabetes. Heart. 2009;95(16):1343-9.

  10. Giannopoulou I, Fernhall B, Carhart R, Weinstock RS, Baynard T, Figueroa A, Kanaley JA. Effects of diet and/or exercise on the adipocytokine and inflammatory cytokine levels of postmenopausal women with type 2 diabetes. Metabolism. 2005;54(7):866-75.

  11. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286(10):1218-27.

  12. Abildgaard J, Johansen MY, Skov-Jeppesen K, Andersen LB, Karstoft K, Hansen KB, Hartmann B, Holst JJ, Pedersen BK, Ried-Larsen M. Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial. Med Sci Sports Exerc. 2022;54(1):38-46.

  13. Barakat R, Refoyo I, Coteron J, Franco E. Exercise during pregnancy has a preventative effect on excessive maternal weight gain and gestational diabetes. A randomized controlled trial. Braz J Phys Ther. 2019;23(2):148-55.

  14. Li Z, Cheng Y, Wang D, Chen H, Chen H, Ming W, et al. Incidence Rate of Type 2 Diabetes Mellitus after Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of 170,139 Women. Journal of Diabetes Research. 2020 Apr 28;2020:1–12.

  15. Davenport MH, Ruchat SM, Poitras VJ, Jaramillo Garcia A, Gray CE, Barrowman N, et al. Prenatal exercise for the prevention of gestational diabetes mellitus and hypertensive disorders of pregnancy: a systematic review and meta-analysis. British Journal of Sports Medicine. 2018 Oct 18;52(21):1367–75.

  16. Impact of Intensive Lifestyle Intervention on Depression and Health-Related Quality of Life in Type 2 Diabetes: The Look AHEAD Trial. Diabetes Care. 2014 May 22;37(6):1544–53.

  17. Cooke S, Pennington K, Jones A, Bridle C, Smith MF, Curtis F. Effects of exercise, cognitive, and dual-task interventions on cognition in type 2 diabetes mellitus: A systematic review and meta-analysis. Sunderland C, editor. PLOS ONE. 2020 May 14;15(5):e0232958.

  18. Williamson DA, Rejeski J, Lang W, Van Dorsten B, Fabricatore AN, Toledo K, Look ARG. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med. 2009;169(2):163-71.

  19. Hordern MD, Dunstan DW, Prins JB, Baker MK, Singh MA, Coombes JS. Exercise prescription for patients with type 2 diabetes and pre-diabetes: a position statement from Exercise and Sport Science Australia. J Sci Med Sport. 2012;15(1):25-31.

  20. Kanaley JA, Colberg SR, Corcoran MH, Malin SK, Rodriguez NR, Crespo CJ, et al. Exercise/Physical Activity in Individuals with Type 2 Diabetes: A Consensus Statement from the American College of Sports Medicine. Medicine & Science in Sports & Exercise [Internet]. 2022 Feb;54(2):353–68. Available from: https://pubmed.ncbi.nlm.nih.gov/35029593/

  21. Dempsey PC, Larsen RN, Sethi P, Sacre JW, Straznicky NE, Cohen ND, et al. Benefits for Type 2 Diabetes of Interrupting Prolonged Sitting With Brief Bouts of Light Walking or Simple Resistance Activities. Diabetes Care. 2016 Apr 13;39(6):964–72.

  22. Turner G, Quigg S, Davoren P, Basile R, McAuley SA, Coombes JS. Resources to Guide Exercise Specialists Managing Adults with Diabetes. Sports Medicine - Open. 2019 Jun 3;5(1).

  23. Borhade MB, Singh S. Diabetes and Exercise [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Nov 8]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526095/#_ncbi_dlg_citbx_NBK526095

p20 – 21 Prescribing exercise

  1. Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes. 2019 Jul 8;12:1057-1072. doi: 10.2147/DMSO.S186600. PMID: 31372016; PMCID: PMC6630094.

  2. Ueda SY, Nakahara H, Miyamoto T. Effects of exercise on glucagon-like peptide-1 (GLP-1). The Journal of Physical Fitness and Sports Medicine. 2013 May 25;2(2):221-4.

  3. Hallworth JR. The influence of exercise intensity on appetite regulating hormones GLP-1 and PYY in active healthy adults. University of Lethbridge (Canada); 2016.

  4. Hallworth JR, Copeland JL, Doan J, Hazell TJ. The effect of exercise intensity on total PYY and GLP-1 in healthy females: a pilot study. Journal of nutrition and metabolism. 2017 Feb 13;2017.

  5. Lee SS, Yoo JH, So YS. Effect of the low-versus high-intensity exercise training on endoplasmic reticulum stress and GLP-1 in adolescents with type 2 diabetes mellitus. Journal of physical therapy science. 2015;27(10):3063-8.

  6. Malin SK, Huang H, Mulya A, Kashyap SR, Kirwan JP. Lower dipeptidyl peptidase-4 following exercise training plus weight loss is related to increased insulin sensitivity in adults with metabolic syndrome. Peptides. 2013 Sep 1;47:142-7.

  7. Boulé NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. Jama. 2001 Sep 12;286(10):1218-27.

  8. Sigal RJ, Boulé NG, Kenny G. Exercise and Glycemic Control in Diabetes—Reply. JAMA. 2001 Dec 19;286(23):2941-2.

  9. Way KL, Hackett DA, Baker MK, Johnson NA. The effect of regular exercise on insulin sensitivity in type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes & metabolism journal. 2016 Aug 2;40(4):253-71.

  10. Pan B, Ge L, Xun YQ, Chen YJ, Gao CY, Han X, Zuo LQ, Shan HQ, Yang KH, Ding GW, Tian JH. Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. International Journal of Behavioral Nutrition and Physical Activity. 2018 Dec;15(1):1-4.

  11. Turner G, Quigg S, Davoren P, Basile R, McAuley SA, Coombes JS. Resources to guide exercise specialists managing adults with diabetes. Sports Medicine-Open. 2019 Dec;5(1):1-2.

  12. Johnson NA, Sultana RN, Brown WJ, Bauman AE, Gill T. Physical activity in the management of obesity in adults: A position statement from Exercise and Sport Science Australia. Journal of Science and Medicine in Sport. 2021 Dec 1;24(12):1245-54.

  13. Hordern MD, Dunstan DW, Prins JB, Baker MK, Singh MA, Coombes JS. Exercise prescription for patients with type 2 diabetes and pre-diabetes: a position statement from Exercise and Sport Science Australia. Journal of Science and Medicine in Sport. 2012 Jan 1;15(1):25-31.

  14. Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, Horton ES, Castorino K, Tate DF. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes care. 2016 Nov;39(11):2065.Exercise management in type 1 diabetes: a consensus statements

p22 – 23 Helping people with diabetes to prepare for emergencies

  1. Allweiss P. Diabetes and Disasters: Recent Studies and Resources for Preparedness. Curr Diab Rep. 2019 Nov 20;19(11):131. doi: 10.1007/s11892-019-1258-7. PMID: 31748930.

  2. Ghazanchaei E, Khorasani-Zavareh D, Aghazadeh-Attari J, Mohebbi I. Identifying and Describing Impact of Disasters on Non-Communicable Diseases: A Systematic Review. Iran J Public Health. 2021 Jun;50(6):1143-1155. doi: 10.18502/ijph.v50i6.6413. PMID: 34540735; PMCID: PMC8410956.

  3. Miller AC, Arquilla B. Chronic diseases and natural hazards: impact of disasters on diabetic, renal, and cardiac patients. Prehosp Disaster Med. 2008 Mar-Apr;23(2):185-94. doi: 10.1017/s1049023x00005835. PMID: 18557300.

  4. Diabetes Australia and the Australian Diabetes Educators Association. 2021. The needs of people with diabetes and other chronic conditions in natural disasters and emergencies: A guide for emergency services, local councils and the not-for-profit sector. https://www.ndss.com.au/wp-content/uploads/resources/booklet-emergency-guide-services-councils-not-for-profit.pdf (accessed October 2023)

  5. De Rubeis V, Lee J, Anwer MS, Yoshida-Montezuma Y, Andreacchi AT, Stone E, Iftikhar S, Morgenstern JD, Rebinsky R, Neil-Sztramko SE, Alvarez E, Apatu E, Anderson LN. Impact of disasters, including pandemics, on cardiometabolic outcomes across the life-course: a systematic review. BMJ Open. 2021 May 3;11(5):e047152. doi: 10.1136/bmjopen-2020-047152. PMID: 33941635; PMCID: PMC8098961.

p24-26 Popular weight loss diets compared

  1. Australian Institute of Health and Welfare. Diabetes: Australian Facts Canberra2023 [Available from: https://www.aihw.gov.au/reports/diabetes/diabetes/contents/total-diabetes/type-2-diabetes.

  2. Grant B, Sandelson M, Agyemang-Prempeh B, Zalin A. Managing obesity in people with type 2 diabetes. Clin Med (Lond). 2021;21(4):e327-e231.

  3. Wilding JP. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract. 2014;68(6):682-91.

  4. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541-51.

  5. Royal Australian College of General Practitioners (RACGP). Management of type 2 diabetes: A handbook for general practice. 2020.

  6. Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KHK, MacLeod J, et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care. 2019;42(5):731-54.

  7. Markovic TP, Proietto J, Dixon JB, Rigas G, Deed G, Hamdorf JM, et al. The Australian Obesity Management Algorithm: A simple tool to guide the management of obesity in primary care. Obes Res Clin Pract. 2022;16(5):353-63.

  8. National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults, adolescents and children in Australia. In: National Health and Medical Research Council, editor. Melbourne2013.

  9. Healthy Eating Active Living - 8700 app [Internet]. www.healthyliving.nsw.gov.au. Available from: https://www.healthyliving.nsw.gov.au/8700-app

  10. Gibson AA, Franklin J., Sim, K. A., Partridge S .R., Caterson, I. D. Lifestyle approaches to obesity: Making it a less weighty issue. Endocrinology Today. 2013;2(4):8-15.

  11. Franklin LJS, A. N.; Gibson, A. A.; Caterson, I. D. Adjunctive therapies for obesity: Pharmacotherapy, VLEDs and bariatric surgery. Medicine Today. 2020;21(10):21-9.

  12. Maston G, Franklin J, Gibson AA, Manson E, Hocking S, Sainsbury A, et al. Attitudes and Approaches to Use of Meal Replacement Products among Healthcare Professionals in Management of Excess Weight. Behav Sci (Basel). 2020;10(9).

  13. Gibson AA, Franklin J, Pattinson AL, Cheng ZG, Samman S, Markovic TP, et al. Comparison of Very Low Energy Diet Products Available in Australia and How to Tailor Them to Optimise Protein Content for Younger and Older Adult Men and Women. Healthcare (Basel). 2016;4(3).

  14. https://diabetesjournals.org/care/article/doi/10.2337/dc23-0781/153542/Intensive-Lifestyle-Intervention-for-Remission-of

  15. Borgundvaag E, Mak J, Kramer CK. Metabolic Impact of Intermittent Fasting in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Interventional Studies. J Clin Endocrinol Metab. 2021;106(3):902-11.

  16. Dietitians Australia. Intermittent fasting: Dietitians Australia; 2023 [Available from: https://www.diabetesaustralia.com.au/blog/intermittent-fasting/.

  17. Sainsbury E, Kizirian NV, Partridge SR, Gill T, Colagiuri S, Gibson AA. Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2018;139:239-52.

  18. Churuangsuk C, Hall J, Reynolds A, Griffin SJ, Combet E, Lean MEJ. Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. Diabetologia. 2022;65(1):14-36.

  19. Goldenberg JZ, Day A, Brinkworth GD, Sato J, Yamada S, Jönsson T, et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. Bmj. 2021;372:m4743.

  20. Diabetes Australia. Position Statement: Low carbohydrate eating for people with diabetes. Diabetes Australia; 2018.

  21. RACGP - VLED for type 2 diabetes [Internet]. Racgp.org.au. 2018 [cited 2023 Dec 8]. Available from: https://www.racgp.org.au/clinical-resources/clinical-guidelines/handi/handi-interventions/nutrition/vled-for-type-2-diabetes

-- ENDS --